VRAYLAR is a prescription medicine used in adults: along with antidepressant medicines to treat major depressive disorder (MDD) for short-term (acute) treatment of manic or mixed episodes that happen with bipolar I disorder. to treat depressive episodes that happen with bipolar I (dipolar depression)

VRAYLAR works to help control the mood swings of bipolar I disorder in adults, providing full-spectrum relief for all bipolar I symptoms: bipolar I depression and acute manic or mixed episodes. Studies have shown VRAYLAR can: Improve overall depressive and manic symptoms*

For depressive episodes associated with bipolar I disorder, three studies showed Vraylar was significantly superior to placebo at the end of week 6 using the MADRAS total score.

The main neurotransmitters affected by Vraylar are dopamine and serotonin. Dopamine plays a role in causing hallucinations, delusions, and thought disorders.

Vraylar is an atypical antipsychotic that is effective for the treatment of schizophrenia and bipolar disorder. Vraylar is usually well-tolerated and less likely than some other antipsychotics to cause elevations in blood sugar or total cholesterol levels, sedation, or weight gain.

Cariprazine is now FDA-approved as an adjunctive therapy to antidepressants. The US Food and Drug Administration (FDA) has approved AbbVie's cariprazine (Vraylar) as an adjunctive therapy to antidepressants for the treatment of major depressive disorder (MDD) in adults.

VRAYLAR works to help control the mood swings of bipolar I disorder in adults, providing full-spectrum relief for all bipolar I symptoms: bipolar I depression and acute manic or mixed episodes. Studies have shown VRAYLAR can: Improve overall depressive and manic symptoms*

VRAYLAR works to help control the mood swings of bipolar I disorder in adults, providing full-spectrum relief for all bipolar I symptoms: bipolar I depression and acute manic or mixed episodes. Studies have shown VRAYLAR can: Improve overall depressive and manic symptoms*

Up to 10% of people taking Vraylar report sleepiness or drowsiness as a side effect; the risk of this side effect increases with higher dosages, and these people may prefer taking it at night.

Studies have shown VRAYLAR can: Improve overall depressive and manic symptoms* Treat mixed episodes (symptoms of depression and mania at the same time)* Reduce the overall severity of the condition.

Cariprazine has an average rating of 5.8 out of 10 from a total of 477 reviews on Drugs.com. 47% of reviewers reported a positive experience, while 36% reported a negative experience.

Vraylar® (cariprazine) is an atypical antipsychotic drug indicated for the treatment of adults with bipolar I disorder, and schizophrenia, as well as an adjunctive treatment for major depressive disorder (MDD) with antidepressants.